AKT is highly phosphorylated in pheochromocytomas but not in benign adrenocortical tumors

被引:41
作者
Fassnacht, M [1 ]
Weismann, D
Ebert, S
Adam, P
Zink, M
Beuschlein, F
Hahner, S
Allolio, B
机构
[1] Univ Wurzburg, Dept Med, Endocrine & Diabet Unit, D-97080 Wurzburg, Germany
[2] Univ Wurzburg, Dept Internal Med 1, D-97080 Wurzburg, Germany
[3] Univ Wurzburg, Inst Pathol, D-97080 Wurzburg, Germany
[4] Univ Freiburg, Endocrine & Diabet Unit, Dept Med 2, D-179106 Freiburg, Germany
关键词
D O I
10.1210/jc.2004-2198
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Activation of AKT plays a major role in a variety of human neoplasias. In mice, a heterozygous deletion of the Pten gene is associated with increased activation of AKT and with development of pheochromocytomas. Objective: The objective of this study was the investigation of the role of AKT in the pathogenesis of pheochromocytomas and adrenocortical tumors. Design, Setting, and Participants: Total AKT and phosphorylated AKT (pAKT) in 15 pheochromocytomas, nine aldosterone-producing adenomas, nine cortisol-producing adenomas, eight adrenocortical carcinomas (ACC), and 15 normal adrenals were investigated by Western blot analysis. Immunohistochemistry for total AKT and pAKT was performed in pheochromocytomas (n = 8), ACC (n = 4), and normal adrenal glands (n = 2). In addition, in pheochromocytomas PTEN protein expression and PTEN loss of heterozygosity were analyzed. Main Outcome Measures: Determination of pAKT/total AKT ratio in adrenal tissues was the main outcome. Results: In comparison to normal adrenals, total AKT-expression was elevated in both pheochromocytomas (193 +/- 22%) and ACC (176 +/- 36%). The pAKT/AKT ratio was significantly increased in pheochromocytomas (338 +/- 49% vs. 100 +/- 11%) but not in ACC, aldosterone-producing adenomas, and cortisol-producing adenomas. No loss of heterozygosity of PTEN and no decrease in PTEN protein was detected in pheochromocytomas. Immunohistochemistry showed strong and homogeneous AKT and pAKT staining in pheochromocytomas and focal staining in ACC. Conclusion: Our findings provide evidence for increased activation of AKT in pheochromocytomas but not in adrenocortical adenomas.
引用
收藏
页码:4366 / 4370
页数:5
相关论文
共 42 条
[1]   Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells -: Protective role in apoptosis [J].
Alvarez-Tejado, M ;
Naranjo-Suárez, S ;
Jiménez, C ;
Carrera, AC ;
Landázuri, MO ;
del Peso, L .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (25) :22368-22374
[2]   The TOR pathway: A target for cancer therapy [J].
Bjornsti, MA ;
Houghton, PJ .
NATURE REVIEWS CANCER, 2004, 4 (05) :335-348
[3]   Fibroblast growth factor-2 inhibits the maturation of pro-insulin-like growth factor-II (Pro-IGF-II) and the expression of insulin-like growth factor finding protein-2 (IGFBP-2) in the human adrenocortical tumor cell line NCI-H295R [J].
Boulle, N ;
Gicquel, C ;
Logié, A ;
Christol, R ;
Feige, JJ ;
Le Bouc, Y .
ENDOCRINOLOGY, 2000, 141 (09) :3127-3136
[4]   Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy [J].
Chang, F ;
Lee, JT ;
Navolanic, PM ;
Steelman, LS ;
Shelton, JG ;
Blalock, WL ;
Franklin, RA ;
McCubrey, JA .
LEUKEMIA, 2003, 17 (03) :590-603
[5]   Cellular survival: a play in three Akts [J].
Datta, SR ;
Brunet, A ;
Greenberg, ME .
GENES & DEVELOPMENT, 1999, 13 (22) :2905-2927
[6]   Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery [J].
Datta, SR ;
Dudek, H ;
Tao, X ;
Masters, S ;
Fu, HA ;
Gotoh, Y ;
Greenberg, ME .
CELL, 1997, 91 (02) :231-241
[7]   Akt and PTEN: New diagnostic markers of non-small cell lung cancer? [J].
David, O .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2001, 5 (04) :430-433
[8]  
De Vita G, 2000, CANCER RES, V60, P3727
[9]   Role of PTEN, a lipid phosphatase upstream effector of protein kinase B, in epithelial thyroid carcinogenesis [J].
Eng, C .
PROTEIN KINASE A AND HUMAN DISEASE, 2002, 968 :213-221
[10]   N-terminal proopiomelanocortin acts as a mitogen in adrenocortical tumor cells and decreases adrenal steroidogenesis [J].
Fassnacht, M ;
Hahner, S ;
Hansen, IA ;
Kreutzberger, T ;
Zink, M ;
Adermann, K ;
Jakob, F ;
Troppmair, J ;
Allolio, B .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (05) :2171-2179